Mersana Therapeutics Stock Price Prediction
| MRSN Stock | USD 29.08 0.18 0.62% |
Momentum 83
Buy Peaked
Oversold | Overbought |
EPS Estimate Next Quarter (2.94) | EPS Estimate Current Year (14.31) | EPS Estimate Next Year (11.11) | Wall Street Target Price 30.75 | EPS Estimate Current Quarter (0.89) |
Using Mersana Therapeutics hype-based prediction, you can estimate the value of Mersana Therapeutics from the perspective of Mersana Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Mersana Therapeutics using Mersana Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Mersana using crowd psychology based on the activity and movement of Mersana Therapeutics' stock price.
Mersana Therapeutics Short Interest
An investor who is long Mersana Therapeutics may also wish to track short interest. As short interest increases, investors should be becoming more worried about Mersana Therapeutics and may potentially protect profits, hedge Mersana Therapeutics with its derivative instruments, or be ready for some potential downside.
200 Day MA 12.2293 | Short Percent 0.0119 | Short Ratio 0.79 | Shares Short Prior Month 53.8 K | 50 Day MA 23.9768 |
Mersana Therapeutics Hype to Price Pattern
Investor biases related to Mersana Therapeutics' public news can be used to forecast risks associated with an investment in Mersana. The trend in average sentiment can be used to explain how an investor holding Mersana can time the market purely based on public headlines and social activities around Mersana Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Mersana Therapeutics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Mersana Therapeutics.
Mersana Therapeutics Implied Volatility | 0.37 |
Mersana Therapeutics' implied volatility exposes the market's sentiment of Mersana Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Mersana Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Mersana Therapeutics stock will not fluctuate a lot when Mersana Therapeutics' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Mersana Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Mersana because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Mersana Therapeutics after-hype prediction price | USD 28.77 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Mersana contract
Based on the Rule 16, the options market is currently suggesting that Mersana Therapeutics will have an average daily up or down price movement of about 0.0231% per day over the life of the 2026-02-20 option contract. With Mersana Therapeutics trading at USD 29.08, that is roughly USD 0.006725 . If you think that the market is fully incorporating Mersana Therapeutics' daily price movement you should consider acquiring Mersana Therapeutics options at the current volatility level of 0.37%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Mersana Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Mersana Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Mersana Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Mersana Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Mersana Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Mersana Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Mersana Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Mersana Therapeutics' historical news coverage. Mersana Therapeutics' after-hype downside and upside margins for the prediction period are 1.44 and 59.40, respectively. We have considered Mersana Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Mersana Therapeutics is unstable at this time. Analysis and calculation of next after-hype price of Mersana Therapeutics is based on 3 months time horizon.
Mersana Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Mersana Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mersana Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Mersana Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
4.45 | 30.63 | 0.31 | 0.04 | 17 Events / Month | 7 Events / Month | In about 17 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
29.08 | 28.77 | 1.07 |
|
Mersana Therapeutics Hype Timeline
Mersana Therapeutics is now traded for 29.08. The entity has historical hype elasticity of -0.31, and average elasticity to hype of competition of -0.04. Mersana is projected to decline in value after the next headline, with the price expected to drop to 28.77. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -1.07%, whereas the daily expected return is now at 4.45%. The volatility of related hype on Mersana Therapeutics is about 382875.0%, with the expected price after the next announcement by competition of 29.04. About 68.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 13.95. Mersana Therapeutics had not issued any dividends in recent years. The entity had 1:25 split on the 28th of July 2025. Given the investment horizon of 90 days the next projected press release will be in about 17 days. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.Mersana Therapeutics Related Hype Analysis
Having access to credible news sources related to Mersana Therapeutics' direct competition is more important than ever and may enhance your ability to predict Mersana Therapeutics' future price movements. Getting to know how Mersana Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Mersana Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| KZR | Kezar Life Sciences | (0.11) | 12 per month | 0.00 | (0.10) | 1.46 | (1.27) | 7.79 | |
| ALGS | Aligos Therapeutics | 0.36 | 9 per month | 0.00 | (0.04) | 10.16 | (8.73) | 28.43 | |
| FGEN | FibroGen | (0.20) | 8 per month | 0.00 | (0.07) | 4.33 | (5.28) | 28.75 | |
| OKUR | OnKure Therapeutics | (0.11) | 12 per month | 4.40 | (0.02) | 9.79 | (6.92) | 23.27 | |
| TPST | Tempest Therapeutics | 0.05 | 6 per month | 0.00 | (0.18) | 7.92 | (9.56) | 57.69 | |
| XFOR | X4 Pharmaceuticals | (0.07) | 17 per month | 3.72 | 0.05 | 9.63 | (5.21) | 36.44 | |
| BRNS | Barinthus Biotherapeutics plc | 0.02 | 7 per month | 0.00 | (0.22) | 5.71 | (9.09) | 24.01 | |
| INMB | INmune Bio | (0.16) | 6 per month | 0.00 | (0.04) | 6.81 | (7.51) | 21.68 | |
| BCAB | Bioatla | 0.13 | 8 per month | 0.00 | (0.08) | 15.28 | (16.25) | 54.11 | |
| XLO | Xilio Development | 0.01 | 8 per month | 0.00 | (0.11) | 4.69 | (5.56) | 15.41 |
Mersana Therapeutics Additional Predictive Modules
Most predictive techniques to examine Mersana price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Mersana using various technical indicators. When you analyze Mersana charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Mersana Therapeutics Predictive Indicators
The successful prediction of Mersana Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Mersana Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Mersana Therapeutics based on analysis of Mersana Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Mersana Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Mersana Therapeutics's related companies. | 2023 | 2024 | 2025 | 2026 (projected) | Current Ratio | 3.36 | 2.19 | 1.97 | 2.82 | Net Debt To EBITDA | 0.85 | 1.25 | 1.44 | 2.0 |
Pair Trading with Mersana Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mersana Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mersana Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Mersana Stock
Moving against Mersana Stock
| 0.78 | DRMA | Dermata Therapeutics Trending | PairCorr |
| 0.66 | SLN | Silence Therapeutics PLC | PairCorr |
| 0.66 | AMRN | Amarin PLC | PairCorr |
| 0.57 | FSTF | First State Financial | PairCorr |
| 0.49 | MREO | Mereo BioPharma Group | PairCorr |
| 0.46 | VINC | Vincerx Pharma Common | PairCorr |
The ability to find closely correlated positions to Mersana Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mersana Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mersana Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mersana Therapeutics to buy it.
The correlation of Mersana Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mersana Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mersana Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mersana Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (13.95) | Revenue Per Share | Quarterly Revenue Growth (0.13) | Return On Assets | Return On Equity |
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.